Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitizing Potential of MOB015B in Healthy Subjects
NCT06369727Phase 1Completed
- Sponsor
- Moberg Pharma AB
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, randomised trial of Terclara in onychomycosis (3 arms), sponsored by Moberg Pharma AB. Primary endpoints: Potential of MOB015B to induce sensitization at 6 weeks and Safety Assessment at 6 weeks. Started Oct 2017; status: completed.
02
Drugs
Terclara
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT06369727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369727.